The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825.
Terri S. Armstrong
Honoraria - Merck
Research Funding - Genentech
Minhee Won
No relevant relationships to disclose
Jeffrey Scott Wefel
Consultant or Advisory Role - Genentech; Roche
Mark R. Gilbert
Consultant or Advisory Role - Genentech; Merck
Honoraria - Merck
Research Funding - Genentech; GlaxoSmithKline
Stephanie L. Pugh
No relevant relationships to disclose
David Brachman
No relevant relationships to disclose
Ritsuko Komaki
No relevant relationships to disclose
Ian R. Crocker
No relevant relationships to disclose
H. Ian Robins
Consultant or Advisory Role - Genentech
R. Jeffrey Lee
No relevant relationships to disclose
Minesh P. Mehta
Consultant or Advisory Role - Genentech; Merck
Stock Ownership - Accuray
Honoraria - Merck
Merideth M Wendland
No relevant relationships to disclose